Literature DB >> 12835231

Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.

Daniela Cilloni, Enrico Gottardi, Milena Fava, Francesca Messa, Sonia Carturan, Alessandro Busca, Angelo Guerrasio, Giuseppe Saglio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12835231     DOI： 10.1182/blood-2003-03-0980

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  12 in total

Review 1.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 2.  Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Authors:  Sabine Kayser; Roland B Walter; Wendy Stock; Richard F Schlenk
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups.

Authors:  M-T Krauth; T Alpermann; U Bacher; C Eder; F Dicker; M Ulke; S Kuznia; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2014-08-11       Impact factor: 11.528

4.  Role of minimal residual disease evaluation in leukemia therapy.

Authors:  Dario Campana
Journal:  Curr Hematol Malig Rep       Date:  2008-07       Impact factor: 3.952

Review 5.  Minimal residual disease quantitation in acute myeloid leukemia.

Authors:  David Shook; Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana
Journal:  Clin Lymphoma Myeloma       Date:  2009

6.  Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.

Authors:  Che Kang Lim; Yeow Tee Goh; William Y K Hwang; Liam Pock Ho; Li Sun
Journal:  Biomark Insights       Date:  2007-08-08

7.  Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Authors:  Hiroto Inaba; Elaine Coustan-Smith; Xueyuan Cao; Stanley B Pounds; Sheila A Shurtleff; Kathleen Y Wang; Susana C Raimondi; Mihaela Onciu; Jeffrey Jacobsen; Raul C Ribeiro; Gary V Dahl; W Paul Bowman; Jeffrey W Taub; Barbara Degar; Wing Leung; James R Downing; Ching-Hon Pui; Jeffrey E Rubnitz; Dario Campana
Journal:  J Clin Oncol       Date:  2012-09-10       Impact factor: 44.544

8.  Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression.

Authors:  Jaroslav Polák; Hana Hájková; Jacqueline Maalaufová-Soukupová; Jana Marková; Cyril Sálek; Jiří Schwarz; Cedrik Haškovec
Journal:  Exp Ther Med       Date:  2011-10-11       Impact factor: 2.447

Review 9.  Status of minimal residual disease testing in childhood haematological malignancies.

Authors:  Dario Campana
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

Review 10.  Immune escape and immunotherapy of acute myeloid leukemia.

Authors:  Luca Vago; Ivana Gojo
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.